GlassScriptPhysician profile
Kathryn J Steenstra
NPI 1265771372
$2,566.96
in general payments reported to CMS, 2019-2025
23 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.34 · 2022: $403 · 2023: $385 · 2024: $465 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $518.87 | 2024-2025 | Carvykti, Rybrevant, Darzalex |
| Jazz Pharmaceuticals INC. | $385.61 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $210.35 | 2025 | |
| Celgene Corporation | $184.09 | 2021-2024 | Reblozyl, Onureg |
| Astellas Pharma US INC | $164.24 | 2022 | |
| Legend Biotech USA INC. | $155.83 | 2025 | Carvykti |
| Abbvie INC. | $122.48 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $112.72 | 2025 | Revuforj |
| Takeda Pharmaceuticals U.S.A., INC. | $107.86 | 2023-2025 | Livtencity |
| Incyte Corporation | $99.20 | 2022-2025 | Jakafi, Niktimvo |
| Sanofi-Aventis U.S. LLC | $86.60 | 2022-2025 | |
| Genmab U.S., INC. | $67.18 | 2024-2025 | Epkinly |
| Amgen INC. | $61.67 | 2022-2024 | Blincyto |
| Novartis Pharmaceuticals Corporation | $52.86 | 2022-2023 | |
| Pfizer INC. | $41.76 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $32.80 | 2023 | Adcetris |
| Rigel Pharmaceuticals, INC. | $29.60 | 2024 | Tavalisse, Rezlidhia |
| Regeneron Healthcare Solutions, INC. | $29.55 | 2025 | Lynozyfic |
| Pharmacyclics LLC, An Abbvie Company | $25.47 | 2023 | Imbruvica, Epkinly |
| Coherus Oncology, INC. | $23.41 | 2024 | |
| Daiichi Sankyo INC. | $23.05 | 2025 | Vanflyta |
| Janssen Scientific Affairs, LLC | $19.73 | 2025 | Talvey |
| Genzyme Corporation | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Steenstra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.